Cell Therapeutics, Inc.

Fred Hutchinson Cancer Center

Stuart L Bursten

Jack W Singer

Glenn C Rice

Paul A Brown

James A Bianco

David A Federighi

Elisa Eiseman

Emer Clarke

There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).

Method for preventing tissue injury from hypoxia

Method for treating diseases mediated by cellular proliferation in

In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.

Method for inhibiting mast cell and basophil activation

There is disclosed a method for screening for inhibitors of cellular second messenger signaling regulated by lysophosphatidic acid acyl transferase (LPAAT) and phosphatidic acid phosphohydrolase (PAPH), which method comprises contacting target cells or appropriate subcullular elements under appropriate conditions of stimulation with a candidate drug and assessing the levels of the relevant subsets of phosphatidic acid (PA) and diacylglycerol (DAG) in the presence and absence of the candidate drug.

Assay for identification therapeutic agents

There is disclosed a diagnostic assay for adult respiratory distress syndrome (ARDS), sepsis, multiple organ dysfunction (MOD) and systemic inflammatory response syndrome (SIRS), comprising (a) measuring the amount of selected unsaturated free fatty acids (FFAs) and saturated FFAs in a body fluid, and (b) determining a ratio value comprising the sum of the unsaturated FFAs divided by the sum of the saturated FFAs. There is further disclosed a diagnostic assay for ARDS, sepsis, MOD and SIRS, comprising (a) measuring the amount of 9- or 13-hydroxyoctadecadienoic acid (HODE) and 5-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HETE) in a body fluid, and (b) determining a ratio value of HETE and HODE.

Sepsis, adult respiratory distress syndrome, and systemic inflammatory

There is disclosed a diagnostic assay for determining the presence of a neoplasia or a tumor burden in a mammal comprising (a) measuring the amount of unsaturated free fatty acids (FFAs) linolenate and arachidonate in a body fluid, and (b) determining a ratio value comprising the sum of linolenate and the sum of arachidonate.

Neoplasia diagnostic method

The specification discloses methods for modulating cellular metabolism in a subject, modulating being desirable to mitigate a condition of the subject. Disclosed methods include processes for administering to said subject an effective amount of a compound of the formula ##STR1## wherein one and only one of R.sup.1 and R.sup.3 is a straight-chain or branched-chain .omega.-hydroxyalkyl (5-8C), or is a branched-chain (.omega.-1)-hydroxyalkyl (5-8C), or is an (.omega.-1)-oxoalkyl (5-8C), or is an (.omega., .omega.-1) or (.omega.-1, .omega.-2)-dihydroxyalkyl (5-8C), or is an alkenyl substituent (5-8C), and the other is alkyl (1-12C) optionally containing one or two non-adjacent oxygen atoms in place of C.

Growing community of inventors

Snoqualmie, WA, United States of America

Stuart L Bursten